Boehringer Ingelheim Lupin Launch $700M Cancer Therapy Collaboration Targeting KRAS

Boehringer Ingelheim, Lupin Launch $700M+ Cancer Therapy Collaboration Targeting KRAS

11:06 EDT 4 Sep 2019 | Genetic Engineering News

Boehringer Ingelheim will partner with Lupin on combination cancer therapies that combine Lupin’s lead MEK inhibitor compound LNP3794 with one of Boehringer Ingelheim’s KRAS inhibitors for gastrointestinal and lung cancer patients with a broad range of oncogenic KRAS mutations.

More From BioPortfolio on "Boehringer Ingelheim, Lupin Launch $700M+ Cancer Therapy Collaboration Targeting KRAS"